When a patient is told their thyroid is "underactive" and prescribed levothyroxine, they are often not told that the reason their thyroid is underactive is that their immune system is attacking it. Hashimoto's thyroiditis — autoimmune thyroiditis — is the underlying cause in the vast majority of hypothyroidism cases in developed countries. Yet many patients and even many physicians treat it as a simple hormone deficiency without addressing its autoimmune root.
What Hashimoto's Actually Is
Hashimoto's thyroiditis is an autoimmune condition in which the immune system produces antibodies (primarily anti-thyroid peroxidase and anti-thyroglobulin antibodies) that attack thyroid tissue. The resulting chronic inflammation gradually destroys thyroid cell function — leading to progressive hypothyroidism over months to years. The rate of progression is highly variable: some patients have antibodies for decades with minimal thyroid destruction; others progress to clinical hypothyroidism within a few years of antibody onset.
The systemic inflammatory burden of Hashimoto's extends beyond the thyroid. Patients with Hashimoto's have elevated systemic inflammatory markers, higher rates of other autoimmune conditions (Type 1 diabetes, celiac disease, lupus, rheumatoid arthritis), higher rates of depression and anxiety, and significant rates of what is termed "Hashimoto's encephalopathy" — cognitive and neurological symptoms driven by the autoimmune process itself, independent of thyroid hormone levels.
The Diagnosis Problem
Hashimoto's is frequently missed for one simple reason: TSH can be completely normal for years while the autoimmune process is actively damaging thyroid tissue. A physician who only tests TSH will see a normal result, tell the patient their thyroid is fine, and miss active Hashimoto's. Testing TPO and thyroglobulin antibodies is the only way to diagnose it — and these tests are not part of standard thyroid screening in most primary care settings.
Treating the Autoimmune Disease, Not Just the Thyroid
Levothyroxine replaces the thyroid hormone that Hashimoto's prevents the thyroid from producing — but it does not address the autoimmune attack on thyroid tissue. For many patients, this is sufficient. For others who have residual symptoms despite optimized thyroid hormone replacement, addressing the underlying immune dysregulation produces additional benefit.
Evidence-based approaches to reducing Hashimoto's autoimmune activity include: selenium supplementation (200 mcg daily has robust evidence from multiple RCTs for reducing TPO antibody levels and thyroid inflammation), strict gluten exclusion (in patients with concurrent celiac disease or non-celiac gluten sensitivity, gluten elimination consistently reduces antibody levels and symptoms), vitamin D optimization (low vitamin D is strongly associated with Hashimoto's severity), stress reduction (cortisol dysregulation directly modulates immune function and autoimmune activity), and low-dose naltrexone (emerging evidence for immune modulation in multiple autoimmune conditions including Hashimoto's).